Get the Stockscreener App
2.94
3.16%
+0.09
Pre-market:
2.94
Mersana Therapeutics Inc stock is currently priced at $2.94, with a 24-hour trading volume of 853.54K.
It has seen a +3.16% increased in the last 24 hours and a -31.63% declined in the past month.
The chart indicates a potential bullish trend, as the stock is above the $2.83 pivot point. If it approaches the $3.00 resistance level, significant changes may occur.
Previous Close:
$2.85
Open:
$2.84
24h Volume:
853.54K
Market Cap:
$356.63M
Revenue:
$36.86M
Net Income/Loss:
$-171.67M
P/E Ratio:
-1.4412
EPS:
-2.04
Net Cash Flow:
$-171.05M
1W Performance:
-9.54%
1M Performance:
-31.63%
6M Performance:
+143.98%
1Y Performance:
-24.42%
1D Range:
$2.76
$2.9575
52W Range:
$0.8014
$9.62
Mersana Therapeutics Inc Stock (MRSN) Company Profile
Name
Mersana Therapeutics Inc
Sector
Industry
Phone
617-498-0020
Address
840 Memorial Drive, Cambridge
Mersana Therapeutics Inc Stock (MRSN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-04-23 | Upgrade | Citigroup | Neutral → Buy |
| Jul-28-23 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jul-27-23 | Downgrade | BTIG Research | Buy → Neutral |
| Jul-27-23 | Downgrade | Citigroup | Buy → Neutral |
| Jul-27-23 | Downgrade | Guggenheim | Buy → Neutral |
| Jul-27-23 | Downgrade | JP Morgan | Neutral → Underweight |
| Jul-27-23 | Downgrade | Truist | Buy → Hold |
| Jul-27-23 | Downgrade | Wedbush | Outperform → Neutral |
| Jun-16-23 | Downgrade | JP Morgan | Overweight → Neutral |
| Jun-15-23 | Initiated | Guggenheim | Buy |
| Mar-16-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Jan-20-23 | Initiated | Citigroup | Buy |
| Nov-21-22 | Initiated | Truist | Buy |
| Oct-15-21 | Resumed | BTIG Research | Buy |
| Aug-30-21 | Initiated | H.C. Wainwright | Buy |
| Mar-31-21 | Initiated | Credit Suisse | Neutral |
| Dec-03-20 | Initiated | Stifel | Buy |
| Sep-29-20 | Resumed | JP Morgan | Neutral |
| Apr-29-20 | Initiated | BTIG Research | Buy |
| Jan-21-20 | Reiterated | H.C. Wainwright | Buy |
| Mar-11-19 | Downgrade | JP Morgan | Neutral → Underweight |
| Nov-14-18 | Upgrade | Leerink Partners | Mkt Perform → Outperform |
| May-08-18 | Initiated | Robert W. Baird | Outperform |
| Mar-19-18 | Downgrade | JP Morgan | Overweight → Neutral |
View All
Mersana Therapeutics Inc Stock (MRSN) Latest News
Strength Seen in Curis (CRIS): Can Its 19.5% Jump Turn into More Strength?
Zacks Investment Research
Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire Inc.
The Analyst Verdict: Mersana Therapeutics In The Eyes Of 5 Experts
Benzinga
Why Butterfly Network Shares Are Trading Lower By 22%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Benzinga
Hormel Foods Reports Upbeat Earnings, Joins Pure Storage, Okta, Papa John's International And Other Big Stocks Moving Higher On Thursday
Benzinga
Expert Outlook: Mersana Therapeutics Through The Eyes Of 5 Analysts
Benzinga
Mersana Therapeutics Inc Stock (MRSN) Financials Data
Mersana Therapeutics Inc (MRSN) Revenue 2024
MRSN reported a revenue (TTM) of $36.85 million for the quarter ending December 31, 2023, a +38.65% rise year-over-year.
Mersana Therapeutics Inc (MRSN) Net Income 2024
MRSN net income (TTM) was -$171.67 million for the quarter ending December 31, 2023, a +15.94% increase year-over-year.
Mersana Therapeutics Inc (MRSN) Cash Flow 2024
MRSN recorded a free cash flow (TTM) of -$171.05 million for the quarter ending December 31, 2023, a -231.75% decrease year-over-year.
Mersana Therapeutics Inc (MRSN) Earnings per Share 2024
MRSN earnings per share (TTM) was -$1.50 for the quarter ending December 31, 2023, a +31.51% growth year-over-year.
About Mersana Therapeutics Inc
Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company focusing on the development of oncology therapeutics in the United States and Canada. The company develops Dolaflexin, an antibody drug conjugate (ADC) platform designed to enhance the potency and efficacy of ADCs while simultaneously enhancing the safety and tolerability. Its lead product candidates include XMT-1522, an ADC targeting HER2-expressing tumors, which is in Phase I clinical trial for treating patients with breast cancer, non-small-cell-lung-cancer (NSCLC), and gastric cancer; and XMT-1536, an ADC targeting NaPi2b that is in Phase I clinical trial for the treatment of patients with ovarian cancer, NSCLC, and other cancers. Mersana Therapeutics, Inc. has strategic alliances with Takeda Pharmaceutical Company Limited; Merck KGaA; and Asana BioSciences, LLC. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2002 and is based in Cambridge, Massachusetts.
1.53%
3.38%
Cap:
|
Volume (24h):